Researchers have discovered the biological mechanisms that the herpes virus uses to infect people, potentially leading to a new generation of drug therapies.
French biotech Abivax might be on the verge of HIV cure and prevention discovery, after achieving a significant reduction of viral load patients during the first 28 days of treatment.
The UK could find its ability to counter the threat of a ‘super-gonorrhoea’ and other infectious diseases hampered if the country loses access to the EU’s early warning health system, the B
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.